Resources from the same session
Invited discussant abstracts 345PD and 352PD
Presenter: Ignacio Melero
Session: Melanoma and immunotherapy
Resources:
Presentation
Webcast
Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non–small cell lung cancer
Presenter: Keiichi Ota
Session: Melanoma and immunotherapy
Resources:
Abstract
Evaluation of safety, tolerability, pharmacokinetics (PK) and efficacy of dabrafenib and trametinib combination (Dab + Tra) therapy in Japanese patients (pts) with BRAF V600 mutation-positive advanced cutaneous melanoma: a phase (Ph) I/II study
Presenter: Arata Tsutsumida
Session: Melanoma and immunotherapy
Resources:
Abstract
Cost-effectiveness of nivolumab in combination with ipilimumab in patients with unresectable advanced melanoma in Australia
Presenter: Megan Bohensky
Session: Melanoma and immunotherapy
Resources:
Abstract
BRAF mutation status – a good prognostic indicator in the era of targeted therapies?
Presenter: Luke McLean
Session: Melanoma and immunotherapy
Resources:
Abstract
A phase I study of pegylated interferon alfa-2b as an adjuvant therapy in Japanese patients with malignant melanoma
Presenter: Shusuke Yoshikawa
Session: Melanoma and immunotherapy
Resources:
Abstract
A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma
Presenter: Shanshan Jiang
Session: Melanoma and immunotherapy
Resources:
Abstract
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.